tirzepatide weight loss results Success Stories: Real You Need to See Tirzepatide 8-Week Weight Loss Program

A variant in the GLP1R gene is associated with differences in weight loss, while a variant in the GIPR gene predicts nausea specifically in people taking tirzepatide (Mounjaro), not semaglutide (Wegovy or Ozempic)

The study, which lasts 1.5 years, is split into two components, with participants either receiving trial drug or being assigned to a weight-loss diet in the first component, and all participants receiving the trial drug in the second component

Large-scale observational data adds another layer

This mechanistic difference is central to why the two are studied as a pair

Sharma emphasizes portion control to avoid overeating